Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Trimeris (TRMS)

No earlier versions found for this Subject.

Return to Trimeris (TRMS)

TRMS is a biotech firm engaged in the development of theraputic agents that block viral infection by inhibiting viral fusion with host cells. Their lead product candidate (T-20), inhibits fusion of HIV-1 with host cells. T-20 has been tested in a Phase I/II trial as a MONOTHERAPY for HIV infected patients in the US. Besides being safe & well-tolerated, the 4 patients in the trial who received the higest dose experienced a reduction in viral load to below detectable levels with an assay sensitivity of 500 copies/ml. - (twice as sensitive as the assay Agouron used in their FDA filing). Work will also examine T-20 for use in combination with approved drugs for treatment of HIV. Trimeris also has drug candidates for Respitory Syncytial Virus & Human Parainfluenza Virus.